Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients. They focus on GI drug discovery, innovation, and improving patient outcomes through their products and research. The company is actively involved in clinical trials, presenting research at scientific meetings, and acquiring other biotech companies to expand their pipeline and capabilities.
Industries
Nr. of Employees
large (251-1000)
Ironwood Pharmaceuticals, Inc.
Cambridge, Massachusetts, United States, North America
Patents
Compositions for colon cleansing and the treatment of gastrointestinal disorders
US-10618938-B2
View Details
Compositions for colon cleansing and the treatment of gastrointestinal disorders
US-10618938-B2
View DetailsProducts
Approved GI therapeutic for functional constipation — pediatric indication
Marketed gastrointestinal therapy with an approved pediatric indication for treatment of functional constipation in patients ages 6–17; approval notified via regulatory announcement.
Investigational once-weekly peptide therapy for short bowel syndrome (SBS-IF)
Investigational GI therapeutic candidate evaluated in global Phase III studies for short bowel syndrome with intestinal failure; topline Phase III results publicly announced.
Approved GI therapeutic for functional constipation — pediatric indication
Marketed gastrointestinal therapy with an approved pediatric indication for treatment of functional constipation in patients ages 6–17; approval notified via regulatory announcement.
Investigational once-weekly peptide therapy for short bowel syndrome (SBS-IF)
Investigational GI therapeutic candidate evaluated in global Phase III studies for short bowel syndrome with intestinal failure; topline Phase III results publicly announced.
Expertise Areas
- Clinical trial management
- Pediatric GI clinical development
- Real-world evidence and observational analysis
- Regulatory submissions and approvals (FDA)
Key Technologies
- Phase II/III clinical development
- Real-world evidence analytics
- Pediatric clinical trial design
- Formulation development and CMC methods